Western Australia’s Department of Health has granted medicinal cannabis company Little Green Pharma (LGP) a schedule 9 license to supply psilocybin to eligible license holders under the Medicines and Poisons Act 2014 (WA).
Psilocybin, the active psychedelic compound found in “magic mushrooms” is currently the subject of many clinical trials around the world. Investigations are working to establish the effect of psilocybin on a range of clinical populations, including those with anxiety, depression, eating disorders, Alzheimer’s disease, and substance-use disorder, among others.
The license will enable LGP to supply psilocybin to eligible license holders including researchers around Australia, who currently struggle to obtain the psychedelic needed for trials, forced to obtain psilocybin from the US.
Little Green Pharma will grow the mushrooms at their Perth facility for psilocybin extraction, as this license only allows the extraction of naturally occurring psilocybin. LGP has also applied for a separate license to synthesise and manufacture GMP psilocybin, which would enable the company to produce large quantities of pharmaceutical grade psilocybin in a timely manner.
The company will make use of existing cultivation and manufacturing infrastructure and experience as a major medicinal cannabis supplier to cultivate psilocybin mushrooms for extraction and supply. The company also plans to sponsor a Perth-based clinical trial into psilocybin-assisted psychotherapy, which would be the first psilocybin trial for the state.
Now more than ever, we need reliable and honest contemporary knowledge of psychedelics to be globally accessible. We rely on your support to keep us going; support the dissemination of everything psychedelic with a one-time or recurring contribution and become a Uthymia community member today!
Dr Stephen Bright, co-founder and vice-president of PRISM (Australia’s leading psychedelic research organisation) and senior lecturer in addiction at Edith Cowan University has joined LGP’s clinical advisory board as a foundation member.
It is expected this licensing will enable researchers improved ease of access to the substance, making it more affordable whilst ensuring home grown benefits by keeping production on Aussie shores.